Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

NCT Number	NCT06927635
Lead Sponsor	University Health Network, Toronto
Conditions	Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Enrollment	75 participants
Start Date	2025-07-08
Primary Completion	2030-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-07